Neurotoxicity after hematopoietic stem cell transplant in multiple sclerosis

Accelerated brain volume loss has been noted following immunoablative autologous hematopoietic stem cell transplantation (IAHSCT) for multiple sclerosis. As with other MS treatments, this is often interpreted as ‘pseudoatrophy’, related to reduced inflammation. Treatment‐related neurotoxicity may be contributory. We sought objective evidence of post‐IAHSCT toxicity by quantifying levels of Neurofilament Light Chain (sNfL) and Glial Fibrillary Acidic Protein (sGFAP) before and after treatment as markers of neuroaxonal and glial cell damage.

[1]  H. Atkins,et al.  Does Resetting the Immune System Fix Multiple Sclerosis? , 2019, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[2]  D. Arnold,et al.  High serum neurofilament light chain normalizes after hematopoietic stem cell transplantation for MS , 2019, Neurology: Neuroimmunology & Neuroinflammation.

[3]  B. Sharrack,et al.  Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial , 2019, JAMA.

[4]  Sandra Lee,et al.  Multiple Sclerosis: Destruction and Regeneration of Astrocytes in Acute Lesions , 2019, Journal of neuropathology and experimental neurology.

[5]  J. Kassubek,et al.  Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[6]  J. Kassubek,et al.  Serum GFAP as a biomarker for disease severity in multiple sclerosis , 2018, Scientific Reports.

[7]  H. Atkins,et al.  Autologous hematopoietic stem cell transplantation improves fatigue in multiple sclerosis , 2018, Multiple sclerosis.

[8]  J. Kassubek,et al.  GFAP in early multiple sclerosis: A biomarker for inflammation , 2017, Neuroscience Letters.

[9]  K. Blennow,et al.  Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis , 2017, The Lancet Neurology.

[10]  B. Barres,et al.  Reactive Astrocytes: Production, Function, and Therapeutic Potential. , 2017, Immunity.

[11]  M. Sormani,et al.  Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis , 2017, Nature Reviews Neurology.

[12]  K. Blennow,et al.  Serum neurofilament light as a biomarker for mild traumatic brain injury in contact sports , 2017, Neurology.

[13]  D. Arnold,et al.  Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis , 2017, Multiple sclerosis.

[14]  Henrik Zetterberg,et al.  Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa , 2016, Clinical chemistry and laboratory medicine.

[15]  D. Arnold,et al.  Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial , 2016, The Lancet.

[16]  Cristina Granziera,et al.  Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity , 2016, Multiple sclerosis.

[17]  K. Hermelink.  Chemotherapy and Cognitive Function in Breast Cancer Patients: The So-Called Chemo Brain. , 2015, Journal of the National Cancer Institute. Monographs.

[18]  Daniel C. Lee,et al.  Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis. , 2015, JAMA.

[19]  Vladimir S Fonov,et al.  Jacobian integration method increases the statistical power to measure gray matter atrophy in multiple sclerosis , 2013, NeuroImage: Clinical.

[20]  S. Subramaniam,et al.  Derivation of Neural Stem Cells from Human Adult Peripheral CD34+ Cells for an Autologous Model of Neuroinflammation , 2013, PloS one.

[21]  Andra M. Smith,et al.  Cognitive effects of chemotherapy in breast cancer patients: a dose–response study , 2013, Psycho-oncology.

[22]  Yinshan Zhao,et al.  Characterising aggressive multiple sclerosis , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[23]  Willem Boogerd,et al.  Late effects of high‐dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: Converging results from multimodal magnetic resonance imaging , 2012, Human brain mapping.

[24]  M. Filippi,et al.  Evidence for acute neurotoxicity after chemotherapy , 2010, Annals of neurology.

[25]  David M. Rissin,et al.  Single-Molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations , 2010, Nature Biotechnology.

[26]  B. Andersson,et al.  Busulfan in hematopoietic stem cell transplantation. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[27]  H. Atkins,et al.  Immune ablation followed by autologous hematopoietic stem cell transplantation for the treatment of poor prognosis multiple sclerosis. , 2009, Methods in molecular biology.

[28]  Magdalena Götz,et al.  Origin and progeny of reactive gliosis: A source of multipotent cells in the injured brain , 2008, Proceedings of the National Academy of Sciences.

[29]  Mark Noble,et al.  CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo , 2006, Journal of biology.

[30]  D. Arnold,et al.  Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis , 2006, Neurology.

[31]  Stephen M. Smith,et al.  Accurate, Robust, and Automated Longitudinal and Cross-Sectional Brain Change Analysis , 2002, NeuroImage.

[32]  G. Ebers.  The natural history of multiple sclerosis , 2000, Neurological Sciences.

[33]  J. Baskerville,et al.  The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. , 1991, Brain : a journal of neurology.

[34]  N. Jacobson,et al.  Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. , 1991, Journal of consulting and clinical psychology.

[35]  M. Shelanski,et al.  Sequence of a cDNA clone encoding mouse glial fibrillary acidic protein: structural conservation of intermediate filaments. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J. Vanderhaeghen,et al.  An acidic protein isolated from fibrous astrocytes. , 1971, Brain research.